1. Home
  2. DPRO vs NERV Comparison

DPRO vs NERV Comparison

Compare DPRO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Draganfly Inc.

DPRO

Draganfly Inc.

HOLD

Current Price

$4.62

Market Cap

188.8M

Sector

Industrials

ML Signal

HOLD

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$3.96

Market Cap

210.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DPRO
NERV
Founded
1998
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.8M
210.1M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
DPRO
NERV
Price
$4.62
$3.96
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$15.00
$10.50
AVG Volume (30 Days)
761.4K
136.4K
Earning Date
05-11-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
$158.69
N/A
Revenue Next Year
$131.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.78
$1.93
52 Week High
$14.37
$12.46

Technical Indicators

Market Signals
Indicator
DPRO
NERV
Relative Strength Index (RSI) 51.30 42.48
Support Level $4.35 $3.81
Resistance Level $5.69 $4.70
Average True Range (ATR) 0.26 0.34
MACD 0.09 0.01
Stochastic Oscillator 80.47 14.46

Price Performance

Historical Comparison
DPRO
NERV

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: